News for Inhibrx, Inc. (INBX)

In a recent report issued on May 15, 2025, JMP Securities analyst Reni Benjamin reiterated a "Market Perform" rating for Inhibrx Biosciences (INBX). The rating

Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025E

**media[585515]**

PR NewswireSAN DIEGO, March 17, 2025 SAN DIEGO, March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today

Inhibrx (INBX) reports Q4 GAAP EPS of -$3.09, missing estimates by $0.21.

INBX's two main pipeline candidates are entering critical late-stage trials with data readouts expected in mid- to late-2025. Click here to read my analysis.

Global Hyaluronic Acid Market Size, Share & Trends Analysis Report By Grade (Cosmetic Grade, Food Grade, Pharmaceutical Grade), By Application (Aesthetics,...

Advancements and Projections in the Pharmaceutical Intermediates Market: Insights, Trends, Opportunities, and Recent Developments...

Although U.S. stocks closed mixed on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the compa...

Inhibrx Biosciences (INBX) stock gains as CEO purchases 40K shares, raising stake by 5%. Read more here.

ISCG is a passively managed investment vehicle focused on small-cap stocks with appealing growth characteristics. See why the Fund is a Hold.

Earnings call: Lazard announced a net revenue increase to $1.4 billion

Inhibrx stock rated 'Market Perform' by JMP after Sanofi acquisition

Kamada (KMDO stock turned higher as Stifel initiated coverage with a buy rating, highlighting its R&D program targeting a rare lung disorder called AATD. Read more here.

Inhibrx biosciences director buys shares worth over $997,000

Spin-off Links - May 2024 By my count, there have been 7 new US spin-off announcements in 2024. Meanwhile 4 new spin-offs have started trading in the US YTD. Performance as measured by the S&P Spin-off ETF (CSD) has been quite strong with a YTD total return of 12.7% comparing favorably to the SPY. This

NEW YORK, May 10, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...

NEW YORK, March 26, 2024 /PRNewswire/ -- Monteverde & Associates PC , has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services...

NEW YORK, March 18, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...